---
title: "aibio.space: Biotech IR News, Financings and Offerings"
url: "https://aibio.space/"
publisher: "aibio.space"
summary: "The biotech IR desk. Where money meets opportunities. Sourced news on 2,820 biotech companies: offerings, IPOs, going concern. Not investment advice."
---

# The biotech IR desk. Where money meets opportunities.

The biotech IR desk. Where money meets opportunities.

Debt Financing

## [Altimmune draws $10.0 million third tranche from Hercules loan facility](https://aibio.space/news/altimmune-draws-10-0-million-third-tranche-hercules-loan-facility/)

Altimmune drew $10.0 million on October 27, 2026, and the draw extended the interest-only period to June 1, 2028 while adding a minimum cash covenant tied to the loan balance.

A financial district skyline and bay. Photo: Carol M Highsmith, CC0, via rawpixel

- [ALT Altimmune Draws $10.0M Hercules loan tranche](https://aibio.space/news/altimmune-draws-10-0-million-third-tranche-hercules-loan-facility/)
- [INMB INmune Bio Raises $4.50M in registered direct](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)
- [ACTU Actuate Therapeutics Prices $11.0M offering with warrants](https://aibio.space/news/actuate-therapeutics-prices-11-0-million-offering-shares-warrants/)
- [ACRS Aclaris Therapeutics Offering at $3.50, net about $46.7M](https://aibio.space/news/aclaris-therapeutics-prices-49-999-934-stock-pre-funded-warrant/)
- [EQ Equillium $20 million private placement tranche unlocked](https://aibio.space/news/first-eq504-dosing-unlocks-20-million-private-placement-tranche/)
- [AMRN Amarin Settles Hikma patent and antitrust cases](https://aibio.space/news/amarin-settles-hikma-patent-antitrust-cases-generic-vascepa/)
- [PTHS Pelthos Therapeutics Amends Horizon venture loan, funds Loans E to H and adds](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)
- [RGEN REPLIGEN CORP Announces $1.0 billion private convertible notes](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

- [PPCB Propanc Biopharma Nasdaq delisting notice, will appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)
- [PRTA Prothena BMS ends PRX019 license](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)
- [RVPH Reviva Seeks reverse split up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)
- [OSRH OSR Health Nasdaq panel delists shares](https://aibio.space/news/nasdaq-panel-delists-osr-health-1-00-bid-price-rule/)
- [MIST Milestone Pharmaceuticals Nasdaq $1.00 minimum bid notice](https://aibio.space/news/milestone-pharmaceuticals-falls-below-nasdaqs-1-00-minimum-bid-rule/)
- [LENZ LENZ Therapeutics Reorganizes, CEO to step down December 1](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)
- [SGMOQ Sangamo In Chapter 11, July loss $11,165,298](https://aibio.space/news/sangamo-ends-july-chapter-11-16-906-955-cash/)
- [ENLV Enlivex Nasdaq delisting notice, 1-for-16 split](https://aibio.space/news/enlivex-gets-nasdaq-delisting-notice-plans-appeal-1-16-reverse-split/)
- [ARTV Artiva Drops AlloNK, cuts about 94% of staff](https://aibio.space/news/artiva-drops-allonk-cuts-about-94-percent-staff-weighs-strategic/)
- [ATYR aTyr Pharma Sets 1-for-40 reverse split](https://aibio.space/news/atyr-pharma-sets-1-40-reverse-split-shares-trade-adjusted-october-29/)
- [BBNX Beta Bionics Securities class action over iLet](https://aibio.space/news/beta-bionics-discloses-securities-class-action-ilet-statements/)

## Top news

1. Financings · 2026-10-29 [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) [INMB](https://aibio.space/companies/inmune-bio/)
2. Debt Financing · 2026-10-29 [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/) [FOXO](https://aibio.space/companies/foxo-technologies/)
3. Legal · 2026-10-29 [Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena](https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/) [ALNY](https://aibio.space/companies/alnylam-pharmaceuticals/)
4. Listings · 2026-10-29 [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) [RVPH](https://aibio.space/companies/reviva-pharmaceuticals/)
5. Distress · 2026-10-29 [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/) [MLYS](https://aibio.space/companies/mineralys-therapeutics/)
6. Financings · 2026-10-29 [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) [LXEO](https://aibio.space/companies/lexeo-therapeutics/)
7. Legal · 2026-10-29 [Viking and Ligand dispute VK2809 license termination in San Diego court](https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/) [VKTX](https://aibio.space/companies/viking-therapeutics/)[LGND](https://aibio.space/companies/ligand-pharmaceuticals/)
8. Distress · 2026-10-29 [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/) [PRTA](https://aibio.space/companies/prothena/)
9. Financings · 2026-10-29 [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) [PROK](https://aibio.space/companies/prokidney/)
10. Legal · 2026-10-29 [Viking's ITC trade secret ruling against Ascletis is on appeal at Federal Circuit](https://aibio.space/news/vikings-itc-trade-secret-ruling-against-ascletis-appeal-federal/) [VKTX](https://aibio.space/companies/viking-therapeutics/)

Financings

### [Endovia Health Sciences raises equity line ceiling to $135 million](https://aibio.space/news/endovia-health-sciences-raises-equity-line-ceiling-135-million/)

An addendum with C/M Capital Master Fund lifts the facility's maximum commitment from $35 million to $135 million. The filing does not say how much stock has been sold under it.

EDVA

2026-10-27

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Nasdaq gave Propanc no 180-day compliance period because it reverse split within the past year. The company says it will appeal by October 30, 2026. Its fiscal 2026 net loss was $18.9 million.

PPCB

2026-10-29

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Horizon Technology Finance is collateral agent and a lender on the amended loan. The new Loan I and Loan J commitments run to December 31, 2027.

PTHS

2026-10-30

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

The 0.25% notes due 2031 will be issued partly in exchange for 2028 notes and partly for cash, with a conversion price of approximately $226.37.

RGEN

2026-10-30

Company Updates

### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/)

Sephience revenue reached $182 million in the quarter, the company acquired ST-920 for $111.0 million upfront, and it now expects total revenue of $1.29 to $1.32 billion for 2026.

PTCT

2026-10-29

Company Updates

### [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/)

Kiora will pay $3.5 million upfront for exclusive rights outside Asia to KIO-401 from Senju Pharmaceutical. The company plans a multinational Phase 3 trial in CRAO, targeted to start in 2027.

KPRX

2026-10-29

## Investor Rank board

### Most positive view

1. [9 of 10, Most positive view Ascendis Pharma ASND](https://aibio.space/companies/ascendis-pharma/)
2. [9 of 10, Most positive view BeOne Medicines 688235](https://aibio.space/companies/beone-medicines/)
3. [9 of 10, Most positive view Celldex Therapeutics CLDX](https://aibio.space/companies/celldex-therapeutics/)
4. [9 of 10, Most positive view Eli Lilly LLY](https://aibio.space/companies/eli-lilly/)
5. [9 of 10, Most positive view IDEAYA Biosciences IDYA](https://aibio.space/companies/ideaya-biosciences/)

### Most negative view

1. [1 of 10, Most negative view EyePoint EYPT](https://aibio.space/companies/eyepoint/)
2. [2 of 10, Most negative view Summit Therapeutics SMMT](https://aibio.space/companies/summit-therapeutics/)
3. [2 of 10, Most negative view Sarepta Therapeutics SRPT](https://aibio.space/companies/sarepta-therapeutics/)
4. [3 of 10, Negative view Immunovant IMVT](https://aibio.space/companies/immunovant/)
5. [3 of 10, Negative view Fractyl Health GUTS](https://aibio.space/companies/fractyl-health/)

[How the rank works](https://aibio.space/disclosures/#rank)

## Desk views

- [VRTX Vertex spends its cystic fibrosis profits on four new businesses](https://aibio.space/companies/vertex-pharmaceuticals/desk-view/)
- [REGN Regeneron leans on Dupixent while it looks for the next one](https://aibio.space/companies/regeneron-pharmaceuticals/desk-view/)
- [ALNY Alnylam's Amvuttra launch slows as the RNAi pipeline reaches for bigger diseases](https://aibio.space/companies/alnylam-pharmaceuticals/desk-view/)
- [CRSP CRISPR Therapeutics has its product; the bet now is one-time liver editing](https://aibio.space/companies/crispr-therapeutics/desk-view/)
- [BEAM Beam's base editing works in the clinic; selling it is the next test](https://aibio.space/companies/beam-therapeutics/desk-view/)
- [MRNA Moderna's cancer bet pays off in phase 3; now it has to make and market it](https://aibio.space/companies/moderna/desk-view/)

## More news

[Financings](https://aibio.space/financings/) · [Convertible notes](https://aibio.space/debt-financing/) · [Distress](https://aibio.space/distress/) · [Legal](https://aibio.space/legal/) · [Listings](https://aibio.space/listings/) · [Mergers](https://aibio.space/mergers/) · [Weekly report](https://aibio.space/weekly-deals/)

1. Legal · 2026-10-29 [Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits](https://aibio.space/news/court-rules-teva-apotex-vandas-hetlioz-patent-suits/) A Delaware federal court granted summary judgment of non-infringement for Teva and Apotex in September 2026. Vanda is weighing its options, and its 10-Q also reports a DOJ notice and new generic-drug suits. [VNDA](https://aibio.space/companies/vanda-pharmaceuticals/)
2. Legal · 2026-10-29 [Indivior discloses Suboxone dental injury MDL of about 22,098 plaintiffs; no bellwether before 2028](https://aibio.space/news/indivior-discloses-suboxone-dental-injury-mdl-about-22-098-plaintiffs/) Indivior Pharmaceuticals, Inc. is the named defendant in the Northern District of Ohio MDL. Canadian class actions name subsidiaries, and a qui tam case names Indivior Inc. [INDV](https://aibio.space/companies/indivior-pharmaceuticals/)
3. Legal · 2026-10-29 [European patent court rules Enanta patent invalid in Paxlovid suit against Pfizer](https://aibio.space/news/european-patent-court-rules-enanta-patent-invalid-paxlovid-suit/) The Unified Patent Court found the '265 Patent invalid on Pfizer's counterclaim and called Enanta's infringement action unfounded. [ENTA](https://aibio.space/companies/enanta-pharmaceuticals/)
4. Company Updates · 2026-10-28 [Jaguar Health adds six-fold stock plan increase ahead of November vote](https://aibio.space/news/jaguar-health-adds-six-fold-stock-plan-increase-ahead-november-vote/) A proxy supplement filed after a stock dividend explains a six-fold increase in shares available under the 2014 Stock Incentive Plan, which stockholders vote on November 6, 2026. [JAGX](https://aibio.space/companies/jaguar-health/)
5. Listings · 2026-10-28 [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Nasdaq's Hearings Panel determined to delist Glucotrack common stock after its closing bid price was $0.87 on October 14, 2026, and trading is suspended at the open on October 30, 2026. [GCTK](https://aibio.space/companies/glucotrack/)
6. Debt Financing · 2026-10-28 [SANUWAVE gets JPMorgan waiver on fixed charge ratio, tightens limits](https://aibio.space/news/sanuwave-gets-jpmorgan-waiver-fixed-charge-ratio-tightens-limits/) The amendment lowers a prepayment figure and three investment baskets from $500,000 to $250,000 and requires Required Lenders consent for certain acquisitions and equity redemptions. JPMorgan Chase Bank, N.A. is administrative agent. [SNWV](https://aibio.space/companies/sanuwave-health/)
7. Legal · 2026-10-28 [Skye Bioscience faces nimacimab securities class action and two derivative suits](https://aibio.space/news/skye-bioscience-faces-nimacimab-securities-class-action-two-derivative/) Stout v. Skye Bioscience alleges misleading statements about nimacimab from November 4, 2024 to October 3, 2025. Two derivative suits captioned against Dhillon are stayed, and consolidation was sought on August 11. [SKYE](https://aibio.space/companies/skye-bioscience/)
8. Legal · 2026-10-28 [Skye Bioscience faces October 2026 retrial of Cunning whistleblower suit](https://aibio.space/news/skye-bioscience-faces-october-2026-retrial-cunning-whistleblower-suit/) A jury found for former employee Wendy Cunning in 2023. The Ninth Circuit vacated the judgment in 2024. Skye now estimates the legal contingency at $5,417,250 and cites settlement talks. [SKYE](https://aibio.space/companies/skye-bioscience/)
9. Legal · 2026-10-28 [Amarin settles Hikma patent and antitrust cases over generic Vascepa](https://aibio.space/news/amarin-settles-hikma-patent-antitrust-cases-generic-vascepa/) The 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey. [AMRN](https://aibio.space/companies/amarin/)
10. Legal · 2026-10-28 [Replimune 10-Q lists two Massachusetts securities class actions and consolidated derivative suits](https://aibio.space/news/replimune-10-q-lists-two-massachusetts-securities-class-actions/) The first class action was filed shortly after the FDA's first RP1 complete response letter. A motion to dismiss it is due to be fully briefed in December; the SEC closed its probe in June without recommending action. [REPL](https://aibio.space/companies/replimune/)
11. Financings · 2026-10-28 [Actuate Therapeutics prices $11.0 million offering of shares and warrants](https://aibio.space/news/actuate-therapeutics-prices-11-0-million-offering-shares-warrants/) Actuate Therapeutics priced 30,985,900 shares and warrants for 15,492,950 more shares at $0.71 per set, for about $11.0 million before costs. The stock last sold at $0.40, and the company reported $4.4 million of cash at June 30, 2026. [ACTU](https://aibio.space/companies/actuate-therapeutics/)
12. Financings · 2026-10-28 [Adial Pharmaceuticals renames itself Azora Therapeutics after preferred stock vote](https://aibio.space/news/adial-pharmaceuticals-renames-itself-azora-therapeutics-after/) Adial Pharmaceuticals becomes Azora Therapeutics and is expected to trade as AZR from October 29, 2026, after stockholders approved converting the preferred stock issued in its June 2026 acquisition of Azora. The October release does not mention AD04, the drug the company's March 2026 annual report called its lead asset. [ADIL](https://aibio.space/companies/adial-pharmaceuticals/)

## Company highlights

Latest from the companies we cover in depth, with our Investor Rank (opinion only, not a recommendation).

[Alnylam Pharmaceuticals](https://aibio.space/companies/alnylam-pharmaceuticals/) ALNY 7 of 10, Positive view

[Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena](https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/) 2026-10-29

Open the desk

: Alnylam Pharmaceuticals

[Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) VKTX 5 of 10, Neutral view

[Viking and Ligand dispute VK2809 license termination in San Diego court](https://aibio.space/news/viking-ligand-dispute-vk2809-license-termination-san-diego-court/) 2026-10-29

Open the desk

: Viking Therapeutics

[United Therapeutics](https://aibio.space/companies/united-therapeutics/) UTHR 8 of 10, Positive view

[United Therapeutics authorizes another $2 billion share repurchase](https://aibio.space/news/united-therapeutics-authorizes-another-2-billion-share-repurchase/) 2026-10-22

Open the desk

: United Therapeutics

[CSL](https://aibio.space/companies/csl/) CSL 5 of 10, Neutral view

[CSL faces shareholder class action over FY26 guidance and disclosure](https://aibio.space/news/csl-faces-shareholder-class-action-fy26-guidance-disclosure/) 2026-10-22

Open the desk

: CSL

[Fractyl Health](https://aibio.space/companies/fractyl-health/) GUTS 3 of 10, Negative view

[Fractyl cuts about 45% of staff and drops Rejuva gene therapy to fund Revita filing](https://aibio.space/news/fractyl-cuts-about-45-percent-staff-drops-rejuva-gene-therapy-fund/) 2026-10-22

Open the desk

: Fractyl Health

[Arcus Biosciences](https://aibio.space/companies/arcus-biosciences/) RCUS 5 of 10, Neutral view

[Arcus raises $250 million at $17.50 a share a day after kidney cancer data](https://aibio.space/news/arcus-raises-250-million-17-50-share-day-after-kidney-cancer-data/) 2026-10-21

Open the desk

: Arcus Biosciences

[Disc Medicine](https://aibio.space/companies/disc-medicine/) IRON 7 of 10, Positive view

[Disc Medicine raises $450 million at $75 a share after phase 3 win](https://aibio.space/news/disc-medicine-raises-450-million-75-share-after-phase-3-win/) 2026-10-20

Open the desk

: Disc Medicine

[Ultragenyx Pharmaceutical](https://aibio.space/companies/ultragenyx-pharmaceutical/) RARE 6 of 10, Neutral view

[Ultragenyx and Baylor settle Dojolvi patent litigation with Navinta, generic entry set for 2033](https://aibio.space/news/ultragenyx-baylor-settle-dojolvi-patent-litigation-navinta-generic/) 2026-10-19

Open the desk

: Ultragenyx Pharmaceutical

[Silence Therapeutics](https://aibio.space/companies/silence-therapeutics/) SLN 5 of 10, Neutral view

[Merck KGaA agrees to buy Silence Therapeutics for $20 per ADS to get PV drug divesiran](https://aibio.space/news/merck-kgaa-agrees-buy-silence-therapeutics-20-ads-get-pv-drug/) 2026-10-19

Open the desk

: Silence Therapeutics

[EyePoint](https://aibio.space/companies/eyepoint/) EYPT 1 of 10, Most negative view

[EyePoint cuts about half its staff after second Duravyu wet AMD phase 3 miss](https://aibio.space/news/eyepoint-cuts-about-half-staff-after-second-duravyu-wet-amd-phase-3/) 2026-10-19

Open the desk

: EyePoint

[Recursion Pharmaceuticals](https://aibio.space/companies/recursion-pharmaceuticals/) RXRX 5 of 10, Neutral view

[Recursion raises $200 million at $3.25 a share as Sanofi options first candidate](https://aibio.space/news/recursion-raises-200-million-3-25-share-sanofi-options-first-candidate/) 2026-10-15

Open the desk

: Recursion Pharmaceuticals

[Vaxcyte](https://aibio.space/companies/vaxcyte/) PCVX 9 of 10, Most positive view

[Vaxcyte raises about $1.1 billion in stock and convertible notes after phase 3 win](https://aibio.space/news/vaxcyte-raises-about-1-1-billion-stock-convertible-notes-after-phase-3/) 2026-10-09

Open the desk

: Vaxcyte

## News by section

### [Financings](https://aibio.space/financings/)

- [Silexion files to register resale of up to 8,813,531 shares](https://aibio.space/news/silexion-files-register-resale-up-8-813-531-shares/) 2026-10-28 [SLXN](https://aibio.space/companies/silexion-therapeutics/)
- [Aclaris Therapeutics prices $49,999,934 stock and pre-funded warrant offering](https://aibio.space/news/aclaris-therapeutics-prices-49-999-934-stock-pre-funded-warrant/) 2026-10-27 [ACRS](https://aibio.space/companies/aclaris-therapeutics/)
- [Imunon files for share offering with 350% warrant coverage in four tranches](https://aibio.space/news/imunon-files-share-offering-350-percent-warrant-coverage-four-tranches/) 2026-10-27 [IMNN](https://aibio.space/companies/imunon/)
- [Rapport Therapeutics launches stock offering and convertible notes due 2032](https://aibio.space/news/rapport-therapeutics-launches-stock-offering-convertible-notes-due/) 2026-10-27 [RAPP](https://aibio.space/companies/rapport-therapeutics/)
- [Valion Bio sells preferred stock, mostly to settle overdue Series C payments](https://aibio.space/news/valion-bio-sells-preferred-stock-mostly-settle-overdue-series/) 2026-10-27 [VBIO](https://aibio.space/companies/valion-bio/)

### [Debt Financing](https://aibio.space/debt-financing/)

- [VolitionRx prepays $500,000 on Lind note and defers two monthly payments](https://aibio.space/news/volitionrx-prepays-500-000-lind-note-defers-two-monthly-payments/) 2026-10-27 [VNRX](https://aibio.space/companies/volitionrx/)
- [West Pharmaceutical enters $750 million revolver and $200 million term loan](https://aibio.space/news/west-pharmaceutical-enters-750-million-revolver-200-million-term-loan/) 2026-10-26 [WST](https://aibio.space/companies/west-pharmaceutical-services/)
- [China Resources Pharmaceutical issues RMB800 million third tranche of notes](https://aibio.space/news/china-resources-pharmaceutical-issues-rmb800-million-third-tranche/) 2026-10-23 [3320](https://aibio.space/companies/china-resources-pharmaceutical/)
- [Glucotrack sells secured convertible notes and warrants, with Dawson James as placement agent](https://aibio.space/news/glucotrack-sells-secured-convertible-notes-warrants-dawson-james/) 2026-10-22 [GCTK](https://aibio.space/companies/glucotrack/)
- [Integra LifeSciences sells $450 million of 9.500% senior secured notes, refinances credit facility](https://aibio.space/news/integra-lifesciences-sells-450-million-9-500-percent-senior-secured/) 2026-10-19 [IART](https://aibio.space/companies/integra-lifesciences/)

### [Distress](https://aibio.space/distress/)

- [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/) 2026-10-28 [LENZ](https://aibio.space/companies/lenz-therapeutics/)
- [Artiva drops AlloNK, cuts about 94% of staff and weighs strategic alternatives](https://aibio.space/news/artiva-drops-allonk-cuts-about-94-percent-staff-weighs-strategic/) 2026-10-27 [ARTV](https://aibio.space/companies/artiva-biotherapeutics/)
- [Sangamo ends July in Chapter 11 with $16,906,955 in cash](https://aibio.space/news/sangamo-ends-july-chapter-11-16-906-955-cash/) 2026-10-27 [SGMOQ](https://aibio.space/companies/sangamo-therapeutics/)
- [Supernus ends its UBS credit line ahead of the Indivior merger](https://aibio.space/news/supernus-ends-ubs-credit-line-ahead-indivior-merger/) 2026-10-26 [SUPN](https://aibio.space/companies/supernus-pharmaceuticals/)
- [Fractyl cuts about 45% of staff and drops Rejuva gene therapy to fund Revita filing](https://aibio.space/news/fractyl-cuts-about-45-percent-staff-drops-rejuva-gene-therapy-fund/) 2026-10-22 [GUTS](https://aibio.space/companies/fractyl-health/)

### [Legal](https://aibio.space/legal/)

- [Beta Bionics discloses securities class action over iLet statements](https://aibio.space/news/beta-bionics-discloses-securities-class-action-ilet-statements/) 2026-10-27 [BBNX](https://aibio.space/companies/beta-bionics/)
- [Integra LifeSciences details New Jersey class action and two derivative suits in 10-Q](https://aibio.space/news/integra-lifesciences-details-new-jersey-class-action-two-derivative/) 2026-10-23 [IART](https://aibio.space/companies/integra-lifesciences/)
- [CSL faces shareholder class action over FY26 guidance and disclosure](https://aibio.space/news/csl-faces-shareholder-class-action-fy26-guidance-disclosure/) 2026-10-22 [CSL](https://aibio.space/companies/csl/)
- [Medpace discloses plaintiff dropped Ohio securities class action over book-to-bill ratio](https://aibio.space/news/medpace-discloses-plaintiff-dropped-ohio-securities-class-action-book/) 2026-10-22 [MEDP](https://aibio.space/companies/medpace/)
- [SomaLogic stockholder suit heads to 2027 trial without Standard BioTools; Palamedrix claim settled](https://aibio.space/news/somalogic-stockholder-suit-heads-2027-trial-without-standard-biotools/) 2026-10-21 [LAB](https://aibio.space/companies/labiana-health/)

### [Listings](https://aibio.space/listings/)

- [Milestone Pharmaceuticals falls below Nasdaq's $1.00 minimum bid rule](https://aibio.space/news/milestone-pharmaceuticals-falls-below-nasdaqs-1-00-minimum-bid-rule/) 2026-10-28 [MIST](https://aibio.space/companies/milestone-pharmaceuticals/)
- [Nasdaq panel delists OSR Health over $1.00 bid price rule](https://aibio.space/news/nasdaq-panel-delists-osr-health-1-00-bid-price-rule/) 2026-10-28 [OSRH](https://aibio.space/companies/osr-health/)
- [aTyr Pharma sets 1-for-40 reverse split, shares trade adjusted from October 29](https://aibio.space/news/atyr-pharma-sets-1-40-reverse-split-shares-trade-adjusted-october-29/) 2026-10-27 [ATYR](https://aibio.space/companies/atyr-pharma/)
- [CDT Equity seeks votes on reverse splits up to 1-for-1,000 and Astor note shares](https://aibio.space/news/cdt-equity-seeks-votes-reverse-splits-up-1-1-000-astor-note-shares/) 2026-10-27 [CDT](https://aibio.space/companies/cdt-equity/)
- [Enlivex gets Nasdaq delisting notice, plans appeal and 1-for-16 reverse split](https://aibio.space/news/enlivex-gets-nasdaq-delisting-notice-plans-appeal-1-16-reverse-split/) 2026-10-27 [ENLV](https://aibio.space/companies/enlivex/)

### [Mergers](https://aibio.space/mergers/)

- [InMed sets November 5 record date for CVRs tied to Mentari merger](https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/) 2026-10-27 [INM](https://aibio.space/companies/inmed-pharmaceuticals/)
- [Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger](https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/) 2026-10-26 [RLYB](https://aibio.space/companies/rallybio/)
- [Skye Bioscience files preliminary proxy for its Redx Pharma acquisition](https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/) 2026-10-26 [SKYE](https://aibio.space/companies/skye-bioscience/)
- [Bolt Biotherapeutics buys Prana Therapies and raises $120 million](https://aibio.space/news/bolt-biotherapeutics-buys-prana-therapies-raises-120-million/) 2026-10-23 [BOLT](https://aibio.space/companies/bolt-biotherapeutics/)
- [Biotech reverse mergers reach highest count since 2021 as PIPEs return, J.P. Morgan says](https://aibio.space/news/biotech-reverse-mergers-reach-highest-count-since-2021-pipes-return/) 2026-10-21

## 2,820 companies. A desk for each one.

Every listed biotech and pharma company gets its own front page at its own address, with its news and our view of it.

Companies

Companies with a full desk are marked. Every other company shows its listing and our coverage.

## Catalyst calendar Dates the desks are watching, and recent decisions

1. Nov 14, 2026 [Akeso: FDA PDUFA goal date for Summit's ivonescimab BLA in EGFR-mutated NSCLC](https://aibio.space/companies/akeso/) Target date as reported by the company Pending
2. Nov 14, 2026 [Summit Therapeutics: FDA goal date for ivonescimab BLA in EGFR-mutated non-squamous NSCLC](https://aibio.space/companies/summit-therapeutics/) Target date as reported by the company Pending
3. Nov 14, 2026 [Teva Pharmaceutical Industries: FDA action date for at-home use of dexmedetomidine sublingual film, the BioXcel asset Teva bid for](https://aibio.space/companies/teva-pharmaceutical-industries/) Target date as reported by the company Pending
4. Nov 25, 2026 [Sanofi SA: FDA target action date for venglustat in type 3 Gaucher disease](https://aibio.space/companies/sanofi/) Target date as reported by the company Pending
5. Nov 27, 2026 [BridgeBio Pharma: FDA target action date for BBP-418 in LGMD2I/R9](https://aibio.space/companies/bridgebio-pharma/) Target date as reported by the company Pending
6. Nov 27, 2026 [GSK: FDA decision on neladalkib in ALK-positive NSCLC](https://aibio.space/companies/gsk/) Target date as reported by the company Pending

## Where the desks are

2,820

Public drug developers and pharmaceutical makers in our directory, across 58 countries and territories. The US has the most. China, India and South Korea together have more.

Source: aibio.space company directory, research date October 22, 2026. One row per issuer.

### Companies by country

- United States 680
- China 417
- India 219
- South Korea 206
- Taiwan 140
- Japan 93
- Canada 92
- Sweden 74

## Free membership

Read the companies you own in full. Subscribe free and every story, desk and profile opens.

Each desk collects the company's filings, press releases and outside coverage, and adds our view of the science, the odds and the balance sheet.

Free membership

## Free to read. Subscribe to read it all.

Headlines, summaries, the company directory and the opening of every story, desk and profile are open to everyone. Subscribe free with your email to read the rest. In return you agree that we may email you, including offers. One click to unsubscribe.

[How membership works](https://aibio.space/membership/)

---
Source page: https://aibio.space/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "aibio.space: Biotech IR News, Financings and Offerings", 2026-11-02, https://aibio.space/
